CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 25.84% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $9.3 billion (up 2.91% YoY), and the FY2025 full-year result was $2.3 billion, up 1.04% from the prior year.
• Liabilities and Shareholders Equity advanced to $2.7 billion in Q1 2026, from $2.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.7 billion in Q1 2026 to a low of $2.0 billion in Q2 2025.
• A 5-year average of $2.3 billion and a median of $2.2 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 33.11% in 2022, while the deepest fall reached 18.49% in 2022.
• Tracing CRSP's Liabilities and Shareholders Equity over 5 years: stood at $2.2 billion in 2022, then slipped by 0.6% to $2.2 billion in 2023, then gained by 0.56% to $2.2 billion in 2024, then climbed by 1.04% to $2.3 billion in 2025, then gained by 20.33% to $2.7 billion in 2026.
• Business Quant data shows CRSP's Liabilities and Shareholders Equity at $2.7 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.2 billion in Q3 2025.